about
Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodologyNF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritisAnti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanismsRheumatoid arthritis: an overview of new and emerging therapies.Tumor necrosis factor inhibitor therapy for rheumatoid arthritis.Synovial fibroblasts: key players in rheumatoid arthritis.Epigenetics in inflammatory rheumatic diseases.Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.Lipid-derived free radical production in superantigen-induced interstitial pneumonia.Rituximab therapy in Greek patients with rheumatoid arthritisGreen tea and exercise interventions as nondrug remedies in geriatric patients with rheumatoid arthritis.A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.Rheumatoid arthritis-associated microRNA-155 targets SOCS1 and upregulates TNF-α and IL-1β in PBMCs.A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss.Epigenetics in rheumatoid arthritis.The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.The eye: a window of opportunity in rheumatoid arthritis?Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.Selectively induced death of macrophages in the synovial lining of murine knee joints using 10B-liposomes and boron neutron capture synovectomy.[Fibroblasts as pathogenic cells in rheumatic inflammation].Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques.Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis.Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.Characterization of immunogenic properties of polyclonal T cell vaccine intended for the treatment of rheumatoid arthritis.Glucocorticoid receptor variants may predispose to rheumatoid arthritis susceptibility.Involvement of retinoic acid-inducible gene-I in inflammation of rheumatoid fibroblast-like synoviocytes.Functional FCGR3A 158 V/F and IL-6 −174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysisAdalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University HospitalThe prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis
P2860
Q25255941-ACB2BD73-1B71-4BEA-8A78-54A21BFD6576Q33840418-423EE7C1-0ACB-4DC6-98BA-A499ACA7333EQ35228585-8C0B6BA3-BE45-4D18-8947-FCCB7A58B9E1Q36160669-19FBACBC-29E0-4F21-A3FB-85B446E93CABQ36242903-EC1EBC71-EE5A-4805-B315-4091A44F5A7EQ36433286-337077BD-D13F-42DD-A626-0F736D1A1EC6Q36985127-D43E90D0-EF94-4057-B56D-7EE116F77A18Q37120627-FFEA832A-28F7-48C8-BF36-0183118075DFQ37237192-0F57932B-21E2-4E36-A481-1FE265E4E265Q37307871-BCBE1C50-9CAF-4B53-8FA5-F39C8C4F7E9EQ37382183-A54F96A7-B42D-4142-A82A-3C9F111BABEAQ37390483-04D62124-F027-474B-A6A5-06580F3CB803Q37420911-DE1C0C69-2EF5-4D02-A80B-C33BC5AA7863Q37482102-A767B048-BA57-471E-9B61-AE4A71F345BCQ37587047-8C1001A4-90FF-487B-ADBB-AE7FCAD4849FQ37754083-7F5B9F6A-C557-450E-9E34-0C8C9D6A7654Q38219053-06C194BA-DAFC-4351-A0D6-CC571597A4D2Q38753455-C46D2EB1-C47C-468A-92FA-0B95D12DCE7DQ39319086-A4F73FEA-12F9-4FEC-B7E6-174781C4BAF4Q39959544-E72FDE36-3A79-4D19-8B0C-4F8E10903FF6Q40169670-287DB892-69B9-4990-A70E-40BFD7E701A2Q42702064-0B174204-7711-4E48-B09C-BC66F3CE6258Q44774931-572D0E44-522B-4BB1-B021-5864166B7578Q46019776-90CFF17B-B001-48B0-8912-39D4BB73E1CCQ48506716-9AFA4F01-F66D-431C-881B-7AACA68ADCB4Q50736394-FA8CBED0-8664-4B16-9DB2-EF5D22078691Q51802957-CA19E8C7-A098-47CC-A35C-636172128117Q53465020-FF37FAD0-7665-471E-8BEF-69E4DFC119B3Q54513567-C23DBEDC-50EB-4C19-8A35-DD281E299DE0Q54539589-F6D0ADA1-982D-4263-984F-AA2167DB459EQ57330337-B4A9199F-688C-4097-9492-541A095C592BQ57350145-F45E5526-A414-4265-A038-9D4CD04254B8Q57673817-D019C095-FDFC-4694-8BDF-C22368E92858
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Rheumatoid arthritis--a molecular understanding.
@ast
Rheumatoid arthritis--a molecular understanding.
@en
Rheumatoid arthritis--a molecular understanding.
@nl
type
label
Rheumatoid arthritis--a molecular understanding.
@ast
Rheumatoid arthritis--a molecular understanding.
@en
Rheumatoid arthritis--a molecular understanding.
@nl
prefLabel
Rheumatoid arthritis--a molecular understanding.
@ast
Rheumatoid arthritis--a molecular understanding.
@en
Rheumatoid arthritis--a molecular understanding.
@nl
P1476
Rheumatoid arthritis--a molecular understanding.
@en
P2093
J Bruce Smith
Mark K Haynes
P304
P356
10.7326/0003-4819-136-12-200206180-00012
P407
P577
2002-06-01T00:00:00Z